Compare Citius Pharmaceuticals Inc (CTXR) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Manulife Financial Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Manulife Financial Corporation trades at $43.58 (market cap $69.48B). The key difference: Manulife Financial Corporation is far larger — about 5101.3× Citius Pharmaceuticals Inc's market cap, and Manulife Financial Corporation pays a 3.23% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Manulife Financial Corporation for 119 Days on average.
| CTXR | MFC | |
|---|---|---|
Market Cap | $13.62M | $69.48B |
Volume | 132,438 | 1,347,508 |
Sector | Health | Financials |
52-Week High | $1.82 | $44.77 |
52-Week Low | $0.48 | $31.64 |
Typical Hold Time | 16 Days | 119 Days |
Enterprise Value | $3.79M | $64.75B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Manulife Financial (MFC) trades at $41.67, down 2.94% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and executive appointments signal confidence in long-term strategy.
MFC presents a mixed outlook with strong profitability metrics (11.7% net margin, 13.88% ROE) and analyst consensus favoring Buy ratings (57%), but faces technical headwinds and premium valuation concerns. The stock trades above the $34.24 consensus target, suggesting limited near-term upside despite operational strength and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
